Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Abstract 1236: Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia

Cancer Res (2024) 84 (6_Supplement): 1236.

https://doi.org/10.1158/1538-7445.AM2024-1236

Published: 22 March 2024

View article titled, Abstract 1236: Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia

Journal Articles

Abstract 691: Antibody conjugated to a bispecific RNA molecule targeting RIG-I and PLK1

Tony Rady, Stéphane Erb, Safia Deddouche-Grass, Renaud Morales, Hervé Bouchard, Guilhem Chaubet, Sarah Cianférani, Dmitri Wiederschain, Nicolas Basse, Alain Wagner

Cancer Res (2021) 81 (13_Supplement): 691.

https://doi.org/10.1158/1538-7445.AM2021-691

Published: 01 July 2021

View article titled, Abstract 691: Antibody conjugated to a bispecific RNA molecule targeting RIG-I and PLK1

Journal Articles

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Mun Kyung Hwang, Anlai Wang, Zhili Song, Shujia Dai, Bailin Zhang, Joachim Theilhaber, Lily Pao, Dmitri Wiederschain, Chen Zhu

Cancer Res (2021) 81 (13_Supplement): 1632.

https://doi.org/10.1158/1538-7445.AM2021-1632

Published: 01 July 2021

View article titled, Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Journal Articles

Abstract 1887: Anti-CD38/CD28xCD3 trispecific T cell engager induces proliferation of primary T cells and mediates potent killing of primary malignant plasma cells isolated from Multiple Myeloma bone marrow aspirates

Nizar El-Murr, Sahar Kassem, Nadège Carrié, Christophe Henry, Angela Virone-Oddos, Zhi-yong Yang, Dmitri Wiederschain, Helgi Van de Velde, Marielle Chiron, Ludovic Martinet

Cancer Res (2021) 81 (13_Supplement): 1887.

https://doi.org/10.1158/1538-7445.AM2021-1887

Published: 01 July 2021

View article titled, Abstract 1887: Anti-CD38/CD28xCD3 trispecific T cell engager induces proliferation of primary T cells and mediates potent killing of primary malignant plasma cells isolated from Multiple Myeloma bone marrow aspirates

Journal Articles

Abstract 1825: SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors

Wenwen Sha, Sri Vadde, Zhili Song, Edward Seung, Zhen Xing, Liqing Chen, Virna Cortez-Retamozo, Sukhvinder Sidhu, Dinesh Bangari, Lan Wu, Ronnie Wei, Zhi-yong Yang, Gary Nabel, Vasiliki Pelekanou, Michele Sanicola-Nadel, Serena Masciari, Dmitri Wiederschain, Lily Pao

Cancer Res (2021) 81 (13_Supplement): 1825.

https://doi.org/10.1158/1538-7445.AM2021-1825

Published: 01 July 2021

View article titled, Abstract 1825: SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors

Journal Articles

Abstract 1909: Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma

Natalia Malkova, Joachim Theilhaber, Mikhail Levit, Tatiana Tolstykh, Andrew Hebert, Kevin Atchison, Adalis Maisonet, Sara Sara Sinicropi-Yao, Alexei Protopopov, Jack Pollard, Sukhvinder Sidhu, Tun Tun Lin, Lily Pao, Dmitri Wiederschain, Sharad K. Sharma

Cancer Res (2021) 81 (13_Supplement): 1909.

https://doi.org/10.1158/1538-7445.AM2021-1909

Published: 01 July 2021

View article titled, Abstract 1909: Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma

Journal Articles

Abstract 1590: An experimental tumor model resistant to anti-PD-1 is sensitive to local mRNA immunotherapy

Marie Bernardo, Tatiana Tolstykh, Yu-an Zhang, Dinesh S. Bangari, Hui Cao, Kerstin A. Heyl, Joon Sang Lee, Natalia Malkova, Jack Pollard, Hui Qu, Fangxian Sun, Dmitri Wiederschain, Timothy R. Wagenaar

Cancer Res (2021) 81 (13_Supplement): 1590.

https://doi.org/10.1158/1538-7445.AM2021-1590

Published: 01 July 2021

View article titled, Abstract 1590: An experimental tumor model resistant to anti-PD-1 is sensitive to local mRNA immunotherapy

Journal Articles

Abstract 561: Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers

Stephanie Decary, Olivier Lemaitre, Anne-Marie Lefebvre, Alexandra Ferrier, Marielle Chiron, Dmitri Wiederschain, Anne-Sophie Lacoste-Bourgeacq, Nathalie Le Bail, Sukhvinder Sidhu, Cecile Combeau, Mustapha Chadjaa, Celine Nicolazzi

Cancer Res (2020) 80 (16_Supplement): 561.

https://doi.org/10.1158/1538-7445.AM2020-561

Published: 15 August 2020

View article titled, Abstract 561: Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers

Journal Articles

Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models

Natalia V. Malkova, Tatiana Tolstykh, Mikhail Levit, Joachim Theilhaber, Andrew Hebert, Kevin Atchison, Adalis Maisonet, Christian Hotz, Ugur Sahin, Alexei Protopopov, Jack Pollard, Sukhvinder Sidhu, Dmitri Wiederschain, Timothy R. Wagenaar

Cancer Res (2020) 80 (16_Supplement): 4451.

https://doi.org/10.1158/1538-7445.AM2020-4451

Published: 15 August 2020

View article titled, Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models

Journal Articles

Abstract 4321: Integrating multiplex immunohistochemistry (IHC) and transcriptomics for characterization of association between spatial heterogeneity of lymphocytic infiltration and TGFβ pathway activity in solid tumors

Joachim Theilhaber, Jack Pollard, Robert Pomponio, Michele Sanicola-Nadel, Anne Caron, Souâd Naimi, Dmitri Wiederschain, Tun Tun Lin, Rui Wang

Cancer Res (2020) 80 (16_Supplement): 4321.

https://doi.org/10.1158/1538-7445.AM2020-4321

Published: 15 August 2020

View article titled, Abstract 4321: Integrating multiplex immunohistochemistry (IHC) and transcriptomics for characterization of association between spatial heterogeneity of lymphocytic infiltration and TGFβ pathway activity in solid tumors

Journal Articles

Abstract 5179: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Chen Zhu, Celine Nicolazzi, Helgi Van de Velde, Dmitri Wiederschain, Sukhvinder Sidhu, Marielle Chiron

Cancer Res (2020) 80 (16_Supplement): 5179.

https://doi.org/10.1158/1538-7445.AM2020-5179

Published: 15 August 2020

View article titled, Abstract 5179: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Journal Articles

Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors

Zhili Song, Guang Yang, Anlai Wang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Daniel Ajona, Bruno Paiva, Chen Zhu, Dmitri Wiederschain, Marielle F. Chiron Blondel, Francisco Adrian

Cancer Res (2019) 79 (13_Supplement): 2966.

https://doi.org/10.1158/1538-7445.AM2019-2966

Published: 01 July 2019

View article titled, Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors

Journal Articles

Abstract 5024: Treatment with synthetic RIG-I agonist triphosphate RNA leads to local and systemic anti-tumor effects in a mouse melanoma tumor model

Mike W. Helms, Eric Parmantier, Kerstin Jahn-Hofmann, Felix Gnerlich, Lars König, Christiane Metz-Weidmann, Monika Braun, Gabriele Dietert, Kaj Grandien, Joachim Theilhaber, Hui Cao, Tim Wagenaar, Max Schnurr, Stefan Endres, Dmitri Wiederschain, Sabine Scheidler, Simon Rothenfusser, Bodo Brunner

Cancer Res (2019) 79 (13_Supplement): 5024.

https://doi.org/10.1158/1538-7445.AM2019-5024

Published: 01 July 2019

View article titled, Abstract 5024: Treatment with synthetic RIG-I agonist triphosphate RNA leads to local and systemic anti-tumor effects in a mouse melanoma tumor model

Journal Articles

Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)

Cancer Res (2018) 78 (13_Supplement): 1785.

https://doi.org/10.1158/1538-7445.AM2018-1785

Published: 01 July 2018

View article titled, Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)

Journal Articles

Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models

Cancer Res (2018) 78 (13_Supplement): LB-130.

https://doi.org/10.1158/1538-7445.AM2018-LB-130

Published: 01 July 2018

View article titled, Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models

Journal Articles

Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1

Richard C. Gregory, Rita Greco, Hongjing Qu, Natalia Malkova, Mikhail Levit, Keli Perron, Waldemar Racki, Fangxian Sun, Gary Shapiro, Christopher Winter, Dmitri Wiederschain, Tun Tun Lin, Jack Pollard

Cancer Res (2018) 78 (13_Supplement): 2790.

https://doi.org/10.1158/1538-7445.AM2018-2790

Published: 01 July 2018

View article titled, Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1

Journal Articles

Abstract 2489: Sensitivity of liver cancer cell lines to B-catenin knock-down correlates with pathway activation

Cancer Res (2018) 78 (13_Supplement): 2489.

https://doi.org/10.1158/1538-7445.AM2018-2489

Published: 01 July 2018

View article titled, Abstract 2489: Sensitivity of liver cancer cell lines to B-catenin knock-down correlates with pathway activation

Journal Articles

Abstract 5472: Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition

Christophe Henry, Michael Lampa, Timothy He, Beatriz Ospina, Bailin Zhang, Gejing Deng, Claude Barberis, Dietmar Hoffmann, Jack Pollard, Adrian Francisco, Heike Arlt, Jason Reeves, Joshua Murtie, Christopher Winter, Victoria Richon, Hong Cheng, Carlos Garcia-Echeverria, Dmitri Wiederschain, Lakshmi Srinivasan

Cancer Res (2018) 78 (13_Supplement): 5472.

https://doi.org/10.1158/1538-7445.AM2018-5472

Published: 01 July 2018

View article titled, Abstract 5472: Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition

Journal Articles

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Joachim Theilhaber, Jean Cavallo, Stephen L. Madden, Charlene Manning, Sherry Cao, Parminder Mankoo, Robert Pomponio, Hongjing Qu, Natalia Malkova, Gary Shapiro, Christopher Winter, Dmitri Wiederschain, Michele Sanicola-Nadel, Fangxian Sun, Tun Tun Lin, Richard C. Gregory, Jack Pollard

Cancer Res (2018) 78 (13_Supplement): 5550.

https://doi.org/10.1158/1538-7445.AM2018-5550

Published: 01 July 2018

View article titled, Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Journal Articles

Abstract 4787: Targeting miR-21 in hepatocellular carcinoma

Cancer Res (2014) 74 (19_Supplement): 4787.

https://doi.org/10.1158/1538-7445.AM2014-4787

Published: 01 October 2014

View article titled, Abstract 4787: Targeting miR-21 in hepatocellular carcinoma

NARROW

Abstract 1236: Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia

Abstract 691: Antibody conjugated to a bispecific RNA molecule targeting RIG-I and PLK1

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Abstract 1887: Anti-CD38/CD28xCD3 trispecific T cell engager induces proliferation of primary T cells and mediates potent killing of primary malignant plasma cells isolated from Multiple Myeloma bone marrow aspirates

Abstract 1825: SAR443216, a novel trispecific T cell engager with potent T cell-dependent cytotoxicity for HER2-low tumors

Abstract 1909: Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma

Abstract 1590: An experimental tumor model resistant to anti-PD-1 is sensitive to local mRNA immunotherapy

Abstract 561: Preclinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers

Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models

Abstract 4321: Integrating multiplex immunohistochemistry (IHC) and transcriptomics for characterization of association between spatial heterogeneity of lymphocytic infiltration and TGFβ pathway activity in solid tumors

Abstract 5179: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia

Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors

Abstract 5024: Treatment with synthetic RIG-I agonist triphosphate RNA leads to local and systemic anti-tumor effects in a mouse melanoma tumor model

Abstract 1785: Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using Cross-Over-Dual-Variable-Domain (CODV) format for the treatment of acute myeloid leukemia (AML)

Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models

Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1

Abstract 2489: Sensitivity of liver cancer cell lines to B-catenin knock-down correlates with pathway activation

Abstract 5472: Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition

Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy

Abstract 4787: Targeting miR-21 in hepatocellular carcinoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only